Stock Events

Stock Events

Oncovista Innovative Therapies 

$0.000100
2
-$0.00-0% Wednesday 13:30

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0004
52W Low
0.0001
Volume
-
Avg. Volume
-
Mkt Cap
2,355.9
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2013
Q1 2014
Q2 2014
Q3 2014
Q4 2014
Q1 2015
Q2 2015
-0.07
-0.04
-0.02
0.01
Expected EPS
N/A
Actual EPS
-0.0141

Financials

-Profit Margin
Unprofitable
2012
2013
2014
0Revenue
-5.09MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OVIT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. develops oncology drugs that directly compete in the cancer treatment market, similar to Oncovista's focus.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb is involved in the development of various cancer therapies, competing in the same therapeutic areas as Oncovista.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in cancer treatment solutions.
Lilly(Eli) &
LLY
Mkt Cap1.01T
Eli Lilly and Company produces cancer drugs that target similar diseases as Oncovista's products.
Novartis
NVS
Mkt Cap292.07B
Novartis AG specializes in innovative healthcare solutions including oncology, competing in the same market as Oncovista.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. focuses on the development of oncology and hematology drugs, overlapping with Oncovista's market.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. develops therapies for various cancers, competing with Oncovista in the biopharmaceutical oncology sector.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC has a strong focus on cancer drug development, making it a significant competitor in the oncology field.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG is a major player in the oncology market with a comprehensive range of cancer treatments, competing with Oncovista.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson operates in the oncology segment through its pharmaceutical division, directly competing with Oncovista.

About

OncoVista Innovative Therapies, Inc. is a biopharmaceutical firm focused on creating highly specific treatments for cancer. Their methodology involves harnessing tumor-associated biomarkers to target these therapies. The company's investigational drug candidates include Cordycepin (OVI-123), which is currently progressing through Phase I/II clinical trials as a potential therapy for stubborn TdT-positive leukemias. Additionally, L-Nucleoside Conjugates (OVI-117) are in the pre-clinical research phase, being explored for their efficacy against colon cancer. This enterprise was established in 2004 and is based in San Antonio, Texas.
Show more...
CEO
Dr. Alexander L. Weis Ph.D.
Employees
2
Country
United States
ISIN
US68232J1051

Listings

OTC Link
US
OVIT

0 Comments

Share your thoughts

FAQ

What is Oncovista Innovative Therapies stock price today?▼
The current price of OVIT is $0.00 USD — it has decreased by -0% in the past 24 hours. Watch Oncovista Innovative Therapies stock price performance more closely on the chart.
What is Oncovista Innovative Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncovista Innovative Therapies stocks are traded under the ticker OVIT.
Is Oncovista Innovative Therapies stock price growing?▼
OVIT stock has fallen by -0% compared to the previous week, the month change is a -0% fall, over the last year Oncovista Innovative Therapies has showed a -0% decrease.
What is Oncovista Innovative Therapies market cap?▼
Today Oncovista Innovative Therapies has the market capitalization of 2,355.9
What were Oncovista Innovative Therapies earnings last quarter?▼
OVIT earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oncovista Innovative Therapies revenue for the last year?▼
Oncovista Innovative Therapies revenue for the last year amounts to 0 USD.
What is Oncovista Innovative Therapies net income for the last year?▼
OVIT net income for the last year is -5.09M USD.
How many employees does Oncovista Innovative Therapies have?▼
As of June 18, 2026, the company has 2 employees.
In which sector is Oncovista Innovative Therapies located?▼
Oncovista Innovative Therapies operates in the Health & Wellness sector.
When did Oncovista Innovative Therapies complete a stock split?▼
The last stock split for Oncovista Innovative Therapies was on October 29, 2007 with a ratio of 1.4739739:1.
Where is Oncovista Innovative Therapies headquartered?▼
Oncovista Innovative Therapies is headquartered in San Antonio, United States.